MA-HAMAMATSU-PHOTONICS
10.6.2019 05:02:05 CEST | Business Wire | Press release
Hamamatsu Photonics K.K. (TOKYO:6965) has developed a novel 3D fluorescence scanning method called “Zyncscan™” that performs x-z plane scans using a light-sheet for cell-based fluorescence assays in microplates. This technology provides an x-z plane scan using a light-sheet for a whole 96/384/1536-well microplate, allowing users to obtain 3D fluorescence images of whole wells in xy: 2-3 μm and z: 6-7 μm voxel resolution for ≤ 300 μm thickness from the well bottom within a few minutes per color. This technology also allows for ultra-high level separation of cell fluorescence signals from the background, which makes it possible to obtain fluorescence cell images in the cell culture mediums containing serum and with fluorescent dyes (i.e., no need to wash out fluorescent dyes).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005009/en/
Background of development
In drug discovery and development, there is a rapidly growing need to use more physiologically-relevant in vitro cell culture models. These include primary cells, patient-derived cells, human iPSC-derived disease-modeling cells, co-cultures of different types of cells, and 3D cultures such as spheroids and organoids. To develop and advance phenotypic assays and screenings using these physiologically-relevant cellular models, new types of instruments needed to be developed to facilitate high-throughput fluorescence imaging and measurement of heterogeneous 2D and 3D cell cultures. To meet this need, we have developed ZyncscanTM technology that performs an x-z plane scan utilizing a light-sheet for a microplate.
Features of the cell-based fluorescence assays in microplate using Zyncscan™ technology
| 1) | High-speed fluorescence cytometry for 2D monolayer heterogeneous cell culture | |
| A single 120-second scan (one color) for a whole 96/384/1536-well microplate enables fluorescence cytometry of all individual cells in all wells. | ||
| 2) | Single spheroid analyses using depth information (diameter of spheroid; ≤ 200 μm) | |
| A single scan (in just a few minutes) for a microplate enables fluorescence images of spheroids (single or multiple spheroids in a well) in all wells in a 96/384/1536-well microplate. From the images, the entire fluorescence intensity, thickness and volume of each individual spheroid are estimated. | ||
| 3) | Fluorescence images in 3D view (≤ 300 μm) | |
| With a single scan (a few minutes) obtain 3D fluorescence images (300 μm from the bottom of a well) of all wells in a plate. The optical resolution of the image is comparable with the 2x objective of a conventional fluorescence microscope in the x- and y-axes and a 10x objective of confocal fluorescence microscope in the z-axis. | ||
| 4) | In-medium / No dye washout measurement | |
| Measure cellular fluorescence in the medium containing serum and with fluorescent dyes (no need to wash out fluorescent dyes), allowing cells to remain healthy throughout the experiment. | ||
Future outlook
Hamamatsu Photonics K.K. has been developing a fluorescence instrument for cell-based assays equipped with Zyncscan™ technology, CYTOQUBE™, a Light-Sheet Microplate Cytometer. We plan to initiate validation and application experiments in several research sites in drug discovery and development by early 2020. CYTOQUBE™ is planned to be released by the end of the next fiscal year (September 2020).
We will showcase a prototype of the CYTOQUBE™ (Light-Sheet Microplate Cytometer) at the following conferences.
| WPC (World Preclinical Congress) |
| June 17-20, 2019, Boston, MA, USA |
| CYTO |
| June 22-26, 2019, Vancouver, BC, Canada |
Please visit here for more detailed information.
https://www.hamamatsu.com/all/en/news/featured-products_technologies/2019/20190610000000.html
Hamamatsu Photonics K.K.
Hamamatsu Photonics K.K. is a leading manufacturer of photonics devices. We design, manufacture, and sell optical sensors, light sources, optical components, cameras, photometry systems, and measurement/analysis systems.
Web site
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005009/en/
Contact:
Technical Contacts details Hamamatsu Photonics K.K, System Division Business Promotion Department 812, Joko-cho, Higashi-ku, Hamamatsu City, 431-3196 Japan email: export@sys.hpk.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
